Get startedLog in
    Picture of Moberg Pharma AB (publ) logo

    MOB — Moberg Pharma AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapMomentum Trap
    All News

    Sweden's Moberg Pharma Q4 revenue rises

    Picture of Moberg Pharma AB (publ) logoMoberg Pharma AB (publ)
    17/02/2026 07:12
    Overview

Sweden's pharmaceutical firm's Q4 net revenue rises yr/yr

Company signed exclusive license agreement with Karo Healthcare for European markets

Company reported Q4 EBITDA loss of SEK 7.0 mln

Outlook

Moberg Pharma plans European expansion for MOB-015/Terclara® under Lamisil® brand

Regulatory approval needed for MOB-015/Terclara® launch in Europe

Company expects royalty revenues from Karo Healthcare partnership

Result Drivers

MARKET SHARE GAINS - Terclara® increased market share in Sweden and Norway, even during the off season

EUROPEAN EXPANSION - Partnership with Karo Healthcare provides platform for European expansion, leveraging Lamisil® brand

Key Details


    MetricBeat/MissActualConsensus Estimate
    Q4 EPS-SEK 0.27
    Q4 Net Income-SEK 12.80 mln
    Q4 EBIT-SEK 7.50 mln
    Q4 EBITDA-SEK 7 mln
    

Analyst Coverage

Wall Street's median 12-month price target for Moberg Pharma AB (publ) is SEK13.00, about 42.1% above its February 16 closing price of SEK9.15

Press Release: ID:nWkr64pWCw

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on Moberg Pharma AB (publ)

    See all news